Pulmonary Disease, Chronic Obstructive

Respiratory
163
Pipeline Programs
12
Companies
50
Clinical Trials
7
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
1
38
0
78
42
Early DiscoveryClinical DevelopmentMarket

On Market (7)

Approved therapies currently available

Boehringer Ingelheim
ATROVENTApproved
ipratropium bromide
Boehringer Ingelheim
nasal1995
Boehringer Ingelheim
ATROVENT HFAApproved
ipratropium bromide
Boehringer Ingelheim
inhalation2004
U
FLUTICASONE PROPIONATEApproved
fluticasone propionate
Unknown Company
nasal2024
U
FORMOTEROL FUMARATEApproved
formoterol fumarate
Unknown Company
inhalation2024
Boehringer Ingelheim
SPIRIVAApproved
tiotropium bromide
Boehringer Ingelheim
inhalation2004
U
TIOTROPIUM BROMIDEApproved
tiotropium bromide
Unknown Company
inhalation2023
U
TUDORZA PRESSAIRApproved
aclidinium bromide
Unknown Company
inhalation2012

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
214 programs
4
32
76
31
Berodual RespimatPhase 41 trial
Berodual RespimatPhase 41 trial
Combivent Respimat via tee adapterPhase 41 trial
FDC of tiotropium + olodaterolPhase 41 trial
Ipratropium bromide 500 µg/salbutamol sulphate 3 mgPhase 41 trial
+209 more programs
Active Trials
NCT02238132Completed374
NCT02238184Completed105
NCT02236715Completed1,039
+211 more trials
Pfizer
PfizerNEW YORK, NY
5 programs
1
2
1
Spiriva HandiHalerPhase 4
UK-500,001Phase 21 trial
tofimilastPhase 21 trial
UK-369,003Phase 1/21 trial
MISSION COPD - Modern Innovative SolutionS in Improving Outcomes iN COPDN/A1 trial
Active Trials
NCT02534766Completed114Est. Aug 2016
NCT00163098Completed136Est. Dec 2005
NCT00263874Terminated324Est. Sep 2006
+1 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
3 programs
1
1
Metoprolol succinate ERPhase 41 trial
Aclidinium BromidePhase 31 trial
Symbicort in Chronic Obstruktive Pulmonary DiseaseN/A1 trial
Active Trials
NCT00612976Completed18,014
NCT00500318Completed181Est. Sep 2010
NCT03370835Completed21Est. Jun 2008
M&
Merck & Co.RAHWAY, NJ
2 programs
1
formoterol fumaratePhase 41 trial
Vivalink wearable deviceN/A1 trial
Active Trials
NCT05655832CompletedEst. Oct 2023
NCT00139932Completed255Est. Nov 2006
Rocket Pharmaceuticals
1 program
1
XuebijingPhase 41 trial
Active Trials
NCT02937974Unknown254Est. Dec 2018
Novartis
NovartisBASEL, Switzerland
4 programs
1
NVA237Phase 31 trial
Clinical PathwayN/A1 trial
ICS withdrawalN/A
Innate Immune Response in COPDN/A1 trial
Active Trials
NCT03075709Unknown800Est. Sep 2021
NCT02637219Completed30Est. Jan 2008
NCT01837927Withdrawn0Est. Apr 2016
Verona Pharma
Verona PharmaUK - London
2 programs
1
Part A: RPL554Phase 21 trial
self-monitoring for patients with severe COPDN/A1 trial
Active Trials
NCT01513980CompletedEst. May 2014
NCT04027439Completed37Est. May 2019
CT
2 programs
2
3mg TQC3721 Suspension for InhalationPhase 21 trial
TQC3721 inhalation powderPhase 21 trial
Active Trials
NCT06527144CompletedEst. Mar 2025
NCT07252908RecruitingEst. Jun 2026
Mereo BioPharma
Mereo BioPharmaUK - London
1 program
1
BCT197Phase 21 trial
Active Trials
NCT02700919CompletedEst. Nov 2017
Teva
TevaIsrael - Petach Tikva
1 program
Albuterol eMDPI DSN/A1 trial
Active Trials
NCT05241288Completed54Est. Feb 2023
Sanofi
SanofiPARIS, France
1 program
Handling Inhalers - Technique Error Comparison (HI-TEC)N/A1 trial
Active Trials
NCT01794390Completed431Est. Mar 2014
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
High dose or normal dose staphylococcus albicansN/A1 trial
Active Trials
NCT05543343UnknownEst. Aug 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Boehringer IngelheimTiotropium + olodaterol
Boehringer IngelheimTiotropium Respimat®
Boehringer IngelheimStiolto Respimat
Boehringer IngelheimTiotropium
Boehringer IngelheimTiotropium
Rocket PharmaceuticalsXuebijing
Boehringer IngelheimTiotropium
Boehringer IngelheimFDC of tiotropium + olodaterol
Boehringer IngelheimCombivent Respimat via tee adapter
Boehringer Ingelheimtiotropium bromide
Boehringer Ingelheimtiotropium bromide
Boehringer Ingelheimtiotropium
Boehringer IngelheimSpiriva HandiHaler
Boehringer IngelheimTiotropium
Boehringer Ingelheimtiotropium inhalation

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 53,776 patients across 50 trials

NCT04223843Boehringer IngelheimTiotropium + olodaterol

A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale

Start: Jan 2020Est. completion: Sep 2020213 patients
Phase 4Completed
NCT03964207Boehringer IngelheimTiotropium Respimat®

A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)

Start: Nov 2019Est. completion: Nov 202172 patients
Phase 4Completed
NCT03265145Boehringer IngelheimStiolto Respimat

Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

Start: Sep 2017Est. completion: Sep 2020714 patients
Phase 4Completed
NCT03240575Boehringer IngelheimTiotropium

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

Start: Aug 2017Est. completion: May 2019302 patients
Phase 4Completed
NCT03055988Boehringer IngelheimTiotropium

Cardiovascular Function in COPD Patients

Start: Mar 2017Est. completion: Mar 201876 patients
Phase 4Completed
NCT02937974Rocket PharmaceuticalsXuebijing

Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD

Start: Oct 2016Est. completion: Dec 2018254 patients
Phase 4Unknown
NCT02853123Boehringer IngelheimTiotropium

Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients

Start: Sep 2016Est. completion: Aug 2017106 patients
Phase 4Completed
NCT02683109Boehringer IngelheimFDC of tiotropium + olodaterol

Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD

Start: Mar 2016Est. completion: Jan 2017221 patients
Phase 4Completed
NCT01969539Boehringer IngelheimCombivent Respimat via tee adapter

Ventilator Adapters for Combivent Respimat

Start: Oct 2013Est. completion: Nov 201411 patients
Phase 4Terminated
NCT01662986Boehringer Ingelheimtiotropium bromide

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2

Start: Aug 2012Est. completion: Apr 201479 patients
Phase 4Completed
NCT01663987Boehringer Ingelheimtiotropium bromide

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1

Start: Aug 2012Est. completion: May 201479 patients
Phase 4Completed
NCT01483625Boehringer Ingelheimtiotropium

Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection

Start: Nov 2011Est. completion: Dec 2012140 patients
Phase 4Completed
NCT01644734Boehringer IngelheimSpiriva HandiHaler

Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test

Start: Nov 2011Est. completion: Mar 20131,328 patients
Phase 4Completed
NCT01072396Boehringer IngelheimTiotropium

Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease

Start: Feb 2010Est. completion: Nov 2011126 patients
Phase 4Completed
NCT00975195Boehringer Ingelheimtiotropium inhalation

Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease

Start: Feb 2009Est. completion: Jul 20132,488 patients
Phase 4Completed
NCT00563381Boehringer IngelheimTiotropium bromide

Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.

Start: Jan 20087,376 patients
Phase 4Completed
NCT00530842Boehringer IngelheimTiotropium plus Salmeterol

Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD

Start: Sep 2007344 patients
Phase 4Completed
NCT00525512Boehringer Ingelheimtiotropium 18 mcg

Tiotropium In Exercise

Start: Aug 2007519 patients
Phase 4Completed
NCT00523991Boehringer Ingelheimtiotropium

Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).

Start: Apr 2007457 patients
Phase 4Completed
NCT00388882Boehringer Ingelheimtiotropium

Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.

Start: Oct 2006327 patients
Phase 4Completed
NCT00359788Boehringer Ingelheimtiotropium

A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.

Start: Jul 2006349 patients
Phase 4Completed
NCT00267917Boehringer IngelheimBerodual Respimat

Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.

Start: Jan 2006Est. completion: Feb 200613 patients
Phase 4Completed
NCT00153075Boehringer IngelheimBerodual Respimat

Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start: Sep 2005Est. completion: Dec 200519 patients
Phase 4Completed
NCT00139932Merck & Co.formoterol fumarate

Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)

Start: Sep 2005Est. completion: Nov 2006255 patients
Phase 4Completed
NCT00152984Boehringer IngelheimTiotropium inhalation capsules

Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma

Start: Dec 2004Est. completion: Apr 2006472 patients
Phase 4Completed
NCT03370835AstraZenecaMetoprolol succinate ER

Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD

Start: Jun 2004Est. completion: Jun 200821 patients
Phase 4Completed
NCT00106821Boehringer IngelheimTiotropium Bromide Inhalation Powder

Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease

Start: Jun 2004166 patients
Phase 4Completed
NCT00144196Boehringer Ingelheimtiotropium

12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)

Start: Mar 2004Est. completion: Jul 2005224 patients
Phase 4Completed
NCT02172508Boehringer IngelheimTiotropium Inhalation Capsule

Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation

Start: Jan 200415 patients
Phase 4Terminated
NCT00239421Boehringer IngelheimTest: Tiotropium 18 µg per day

A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)

Start: Nov 2003Est. completion: Sep 2004605 patients
Phase 4Completed
NCT00239499Boehringer IngelheimTiotropium

Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)

Start: Sep 2003Est. completion: Aug 2004107 patients
Phase 4Completed
NCT00239408Boehringer IngelheimPulmonary function Testing

Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).

Start: Dec 2002Est. completion: Apr 2004311 patients
Phase 4Completed
NCT00274079Boehringer IngelheimSPIRIVA

SPIRIVA in Ususal Care

Start: Oct 2002Est. completion: Oct 2003395 patients
Phase 4Completed
NCT02182856Boehringer IngelheimIpratropium bromide 500 µg/salbutamol sulphate 3 mg

Ipratropium or Salbutamol Sulphate Alone or Combination Therapy Salbutamol and Ipratropium in Patients With COPD

Start: Feb 199833 patients
Phase 4Completed
NCT02629965Boehringer Ingelheimtiotropium

Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients

Start: Feb 2016Est. completion: Apr 2017184 patients
Phase 3Completed
NCT02296138Boehringer Ingelheimolodaterol

Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

Start: Jan 2015Est. completion: Mar 20177,903 patients
Phase 3Completed
NCT01837927NovartisNVA237

Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.

Start: Apr 2014Est. completion: Apr 20160
Phase 3Withdrawn
NCT02006732Boehringer Ingelheimolodaterol

Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)

Start: Nov 2013Est. completion: Nov 2014809 patients
Phase 3Completed
NCT01964352Boehringer Ingelheimtiotropium

Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)

Start: Nov 2013Est. completion: Nov 2014813 patients
Phase 3Completed
NCT01969721Boehringer Ingelheimfluticasone propionate

Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients

Start: Oct 2013Est. completion: Feb 2015229 patients
Phase 3Completed
NCT01696058Boehringer IngelheimTiotropium

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

Start: Sep 2012Est. completion: Oct 20131,137 patients
Phase 3Completed
NCT01694771Boehringer IngelheimTiotropium

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

Start: Sep 2012Est. completion: Aug 20131,134 patients
Phase 3Completed
NCT01559116Boehringer Ingelheimtiotropium + olodaterol

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

Start: Mar 2012Est. completion: Aug 2013219 patients
Phase 3Completed
NCT01525615Boehringer IngelheimRespimat inhaler

A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD

Start: Feb 2012Est. completion: Sep 2013404 patients
Phase 3Completed
NCT01536262Boehringer IngelheimTiotropium + Olodaterol

Japan Long-term Safety for Tiotropium Plus Olodaterol

Start: Feb 2012Est. completion: Sep 2013122 patients
Phase 3Completed
NCT01431287Boehringer Ingelheimtiotropium + olodaterol

Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Start: Sep 2011Est. completion: Nov 20132,539 patients
Phase 3Completed
NCT01431274Boehringer Ingelheimtiotropium + olodaterol

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Start: Sep 2011Est. completion: Sep 20132,624 patients
Phase 3Completed
NCT01126437Boehringer Ingelheimtiotropium 18 mcg

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Start: May 2010Est. completion: May 201317,183 patients
Phase 3Completed
NCT01040689Boehringer IngelheimOlodaterol

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

Start: Jan 2010108 patients
Phase 3Completed
NCT01040130Boehringer IngelheimOlodaterol

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

Start: Jan 2010151 patients
Phase 3Completed

Related Jobs in Respiratory

Global Medical Affairs Leader, Lung

Johnson & Johnson
Raritan, New Jersey, United States of America
Yesterday
$160K - $276/yr

Propagandista Vendedor Respiratório - Ipatinga ou Governador Valadares/MG

AstraZeneca
Salesforce - Minas Gerais
4d ago

Therapy Area Lead - Lung Oncology

AstraZeneca
London, UK
5d ago

Health Informatics Lead

Sanofi
Reading
6d ago

Associate Director U.S. Marketing, Pulmonologist & IDN Strategy, Respiratory BU

Merck & Co.
USA - Pennsylvania - North Wales (Upper Gwynedd)
1w ago
$142K - $224K/yr

Medical Engagement Lead - Transplant - North Europe

Sanofi
Østerbro
1w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

78 late-stage (Phase 3) programs — potential near-term approvals
12 companies competing in this space

Related Indications

Asthma(378)Chronic Obstructive Pulmonary Disease(123)Idiopathic Pulmonary Fibrosis(90)COPD(74)Chronic Obstructive Pulmonary Disease (COPD)(38)Pulmonary Embolism(27)Respiratory Syncytial Virus Infections(26)Severe Asthma(21)Lung Diseases, Interstitial(19)Pulmonary Fibrosis(15)